Please ensure Javascript is enabled for purposes of website accessibility

Why Johnson & Johnson Stock Is Boosting the Dow

By Brian Stoffel - Apr 16, 2013 at 2:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A beat, combined with impressive numbers from prescription meds, has this company on a run.

Something that sets us Foolish investors apart is that we like to be in control of our own finances. There's nothing wrong with investing in an index fund, but we like to decide which companies will guide us to a financially healthy retirement.

One very popular stock for many a retirement portfolio --including "The World's Greatest" -- reported this morning, and investors are pleased with what they see. Read below to see why this stock -- Johnson & Johnson (JNJ 0.70%) -- is up today, and at the end, I'll offer up access to a special premium report on the company.

Just the numbers



Vs. Expectations

Vs. Q1 2012


$17.5 billion

Beat by $100 million


Earnings Per Share


Beat by $0.04


Sources: E*Trade, SEC filings. These results actually exclude a $600 million, one-time charge for litigation expenses and the company's acquisition of Synthes.  

Because Johnson & Johnson is such a massive medical conglomerate, it helps to break down the company into its three segments:

  1. Consumer: Sells over the counter (OTC) medicines and products, accounting for 21% of all sales.
  2. Pharmaceuticals: Develops prescription medications, accounting for 39% of all sales.
  3. Medical devices and diagnostics: Offers larger, more complicated machines to medical establishments, accounting for 40% of all sales.

Source: SEC filings. 

Source: SEC filings.

Source: SEC filings.

While it might seem that the slow growth in the consumer sector would be disappointing, it actually was encouraging. The last three years have seen sales of Tylenol and Motrin fall as the company addressed production problems at its Puerto Rico and Pennsylvania plants.  

Pharmaceuticals, on the other hand, were both higher than expected and showed tremendous growth. Sales of Invega (a drug for schizophrenia), Stelara (a psoriasis treatment), Simponi (an arthritis medicine), Remicade (an anti-inflammatory), and Prezista (an HIV treatment) all were major contributors to this growth. 

And even though sales for medical devices were softer than expected, they still showed solid 10% growth. That was helped primarily by the acquisition of Synthes, as well as sales of electrophysiology and cardiovascular products, and the company's 1-Day Acuvue disposable contact lenses.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$178.08 (0.70%) $1.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.